Recent studies have revealed that anti-PD-1/PD-L1 blockade improves patient survival in PD-L1-positive patients, and PARP inhibitors have also shown significant tumor response in patients with germline breast cancer associated gene 1/2 (BRCA1/2)-positive advanced TNBC. Here, CD274 is linked to neoplasm.